Trending...
- NextBoat's AI-Powered Marine Marketplace Gains Momentum as Record Growth Signals an Inflection Point for Investors (N Y S E American: NXB)
- Allstream Energy Partners Returns as a Media Partner for the 2026 API Inspection & Mechanical Integrity Summit in San Antonio
- Award-Winning Heritage at South Brunswick Continues to Thrive as One of New Jersey's Premier New Home Communities
DURHAM, N.C., May 27, 2022 /PRNewswire/ -- Accord Healthcare, Inc., a leading generic pharmaceutical company, has added Pemetrexed Lyo. Injection to its line of chemotherapy drugs. The new drug is formulated as a sterile lyophilized (freeze-dried) powder to be reconstituted for intravenous infusion. Pemetrexed Lyo. Injection is therapeutically equivalent to Eli Lilly and Company's ALIMTA® and approved to treat Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Malignant Pleural Mesothelioma (MPM), a cancer of the inside lining of the chest cavity.1 Accord's product is offered in vials of 100mg, 500mg, and 1000mg strengths and is currently available to ship.
Pemetrexed Lyo. Injection is FDA-approved for use as a first-line treatment for locally advanced or metastatic NSCLC with non-squamous tissue type, a maintenance drug for metastatic NSCLC, a treatment for NSCLC that recurs after prior chemotherapy, and a treatment for MPM in patients whose cancer can't be removed surgically.2
"Accord Healthcare US has distinguished itself in oncology injectables, and the introduction of Pemetrexed Lyo. Injection to our portfolio strengthens our offering of oncology medications," said Accord CEO Jeff Hampton. "We are committed to making more generics available to patients. Our technical capabilities and manufacturing infrastructure have defined our company's history and the patients shape our future."
More on ncarol.com
Important Safety Information: Pemetrexed Lyo. Injection may cause fatigue or nausea and vomiting. Other possible side effects are serious, including fast heartbeat, chest pain, blistering and other skin reactions, and difficulty breathing. Pemetrexed is in a class of medications called antifolate antineoplastic agents and works by blocking the action of a certain substance in the body that may help cancer cells multiply.2
Further information about safety and potential side effects can be found in our product insert.
Pemetrexed was approved by the FDA for the treatment of Malignant Pleural Mesothelioma.3 For more information, please visit the Products page at Accord Healthcare US.
About Accord Healthcare US
Accord Healthcare, a wholly owned subsidiary of Intas Pharmaceuticals, is a leading generic pharmaceutical company. Accord is committed to improving lives by increasing access to medicines while also providing novel solutions that enhance the pharmaceutical experience for both healthcare providers and patients. Accord Healthcare combines its advanced manufacturing technology with in-house research to produce highly complex, affordable, and essential medicines. Accord Healthcare's forward-thinking, innovative approach, and its resolve to help patients remains at the heart of everything they do. Accord is headquartered in Durham, North Carolina. The Intas network markets its products in 80 countries. To learn more, visit the Accord website.
More on ncarol.com
References
1 Access data FDA.gov. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021462s021lbl.pdf. Accessed May 2022.
2 Pemetrexed Injection, National Library of Medicine, MedlinePlus. Available at: https://medlineplus.gov/druginfo/meds/a607043.html. Accessed May 2022.
3 FDA drug approval summaries: pemetrexed (Alimta), U.S. Food and Drug Administration. Available at: https://pubmed.ncbi.nlm.nih.gov/15477632/. Accessed May 2022.
Media Contact:
Kellyann Zuzulo
Em-Press Media
[email protected]
215.287.7291
SOURCE Accord Healthcare, Inc.
Pemetrexed Lyo. Injection is FDA-approved for use as a first-line treatment for locally advanced or metastatic NSCLC with non-squamous tissue type, a maintenance drug for metastatic NSCLC, a treatment for NSCLC that recurs after prior chemotherapy, and a treatment for MPM in patients whose cancer can't be removed surgically.2
"Accord Healthcare US has distinguished itself in oncology injectables, and the introduction of Pemetrexed Lyo. Injection to our portfolio strengthens our offering of oncology medications," said Accord CEO Jeff Hampton. "We are committed to making more generics available to patients. Our technical capabilities and manufacturing infrastructure have defined our company's history and the patients shape our future."
More on ncarol.com
- Marcus Christ Announces Singles: "The Hammer Goes Click" and "You Hate Me, I Hate You"
- Nina Simone and Samuel Waymon Music Scholarship Fund Opens 2026/27 Application Cycle
- Fatal FOMO May be Your Last Roll of the Dice
- Inlow Upholstery Offers Dining Chair Reupholstery for Cleveland County Homeowners
- Financial Visionary Kevin Foushee Expands Impact Through MTM LLC and Client-First Advisory Services
Important Safety Information: Pemetrexed Lyo. Injection may cause fatigue or nausea and vomiting. Other possible side effects are serious, including fast heartbeat, chest pain, blistering and other skin reactions, and difficulty breathing. Pemetrexed is in a class of medications called antifolate antineoplastic agents and works by blocking the action of a certain substance in the body that may help cancer cells multiply.2
Further information about safety and potential side effects can be found in our product insert.
Pemetrexed was approved by the FDA for the treatment of Malignant Pleural Mesothelioma.3 For more information, please visit the Products page at Accord Healthcare US.
About Accord Healthcare US
Accord Healthcare, a wholly owned subsidiary of Intas Pharmaceuticals, is a leading generic pharmaceutical company. Accord is committed to improving lives by increasing access to medicines while also providing novel solutions that enhance the pharmaceutical experience for both healthcare providers and patients. Accord Healthcare combines its advanced manufacturing technology with in-house research to produce highly complex, affordable, and essential medicines. Accord Healthcare's forward-thinking, innovative approach, and its resolve to help patients remains at the heart of everything they do. Accord is headquartered in Durham, North Carolina. The Intas network markets its products in 80 countries. To learn more, visit the Accord website.
More on ncarol.com
- Martin A. Sumichrast Joins Hawkeye Systems, Inc. as Chairman of the Board
- Allstream Energy Partners Returns as a Media Partner for the 2026 API Inspection & Mechanical Integrity Summit in San Antonio
- Artists' Lives and Work are Intertwined
- PokerStars & Ladbrokes veteran buys into Finnish news media Rahapelisanomat
- Former Judge Chris Oldner Honored as Best Lawyer by "D Magazine" for 6th Straight Year
References
1 Access data FDA.gov. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021462s021lbl.pdf. Accessed May 2022.
2 Pemetrexed Injection, National Library of Medicine, MedlinePlus. Available at: https://medlineplus.gov/druginfo/meds/a607043.html. Accessed May 2022.
3 FDA drug approval summaries: pemetrexed (Alimta), U.S. Food and Drug Administration. Available at: https://pubmed.ncbi.nlm.nih.gov/15477632/. Accessed May 2022.
Media Contact:
Kellyann Zuzulo
Em-Press Media
[email protected]
215.287.7291
SOURCE Accord Healthcare, Inc.
Filed Under: Business
0 Comments
Latest on ncarol.com
- Achugogo: Tale of the Spring Chaser Wins Inaugural TCCF Prize at Mifa Pitches, the Industry Market of the Annecy International Animation Film Festival
- Everything Policy Launches Madison, an AI Tool That Makes Legislation Readable for Students and Citizens
- TOLI North America Implements Modest Price Increase, Absorbing Majority of Costs
- Is the Market Missing One of the Most Undervalued Cybersecurity Companies on the Stock Market? Cycurion, Inc. (N A S D A Q: CYCU):
- Billion-Dollar Scale Global Technology Powerhouse Being Built with Expanding Government Contracts: Circle8 Group (N A S D A Q: CIRC)
- Nevada Boxing Hall of Fame Gears Up for Star-Studded 14th Annual Induction Gala Weekend
- New Thriller 'Counterframe' Explores the Hidden Vulnerabilities of Modern Society
- Award-Winning Heritage at South Brunswick Continues to Thrive as One of New Jersey's Premier New Home Communities
- Four Seasons Cleaners Debuts Santa Barbara County's First 24/7 Dry Cleaning Kiosk New self-service
- WhereTu Launches to Help Americans Build Successful Lives Abroad
- BoatRegistrationNumbers.com Launches Next-Generation Marine Lettering, Decals and Numbers Tool
- Appliance EMT Expands Built-In and Walk-In Refrigerator Service in Metro Atlanta
- New from Regal House Publishing, Call it Madness: a missing grandfather - reclaiming a ruptured life
- LawProactive Launches SB 37-Compliant Attorney Marketing Software With Exclusive City Territories Across California
- Cogs and Marvel expands EMEA leadership team for next phase of growth
- Dave Freer's "Storm-Dragon" Wins First-Ever Prometheus Special Award For Young Adult Fiction
- T. Jones Group Celebrates Two Wins and Multiple Project Nominations at the 2026 HAVAN Awards
- Studica Robotics Supports Robotics Training Camp for WorldSkills Shanghai 2026
- Lineus Medical Renews Agreement with Vizient, Delivering Enhanced Value for Vizient Members
- Qscription Technologies Appoints Radiology Industry Veteran Elliot Silverman to Advisory Board